about
Involvement of long noncoding RNAs in diseases affecting the central nervous systemNasal vaccine innovation.Inactivated influenza vaccines: recent progress and implications for the elderly.Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensNovel antigen delivery systems.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyInfluenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineageParticulate delivery systems for vaccines: what can we expect?Clinical applications of virosomes in cancer immunotherapy.Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.Artificial cells: from basic science to applications.Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen.Topical and mucosal liposomes for vaccine delivery.Influenza virosomes as a vaccine adjuvant and carrier system.Bio-inspired, bioengineered and biomimetic drug delivery carriers.Evasion of influenza A viruses from innate and adaptive immune responses.Influenza virosomes as vaccine adjuvant and carrier system.A review on proniosomal drug delivery system for targeted drug actionExtracellular vesicles: potential roles in regenerative medicineIn vitro and ex vivo strategies for intracellular delivery.Cellular delivery of siRNA mediated by fusion-active virosomes.Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA.Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.Targeted Delivery of Protein Drugs by Nanocarriers.Virosomes can enter cells by non-phagocytic mechanisms
P2860
Q26852160-0355FD87-6ECA-4F61-95EF-9CA9D5F8CB72Q30395810-7174335A-2ACA-4442-90AD-3654884808ACQ30399057-02E1C33D-1B8A-4CB0-821F-84D65DAB5A65Q35664854-FFEC29DA-C336-4B80-9BAE-D12EB90F6F71Q35812875-C370CA03-66CD-408A-9A00-E839122A4F64Q35947894-C204F5A1-4F9E-4495-BAFB-E10E006870FEQ36116250-8B37606C-A488-4208-B8F5-BB472A9FB3A8Q36376605-65FD1328-CF6B-4C96-AC8F-60136EA3909EQ36492598-52339AF6-6144-4C62-88C5-042D487F19A8Q36627236-82A2602E-3AF9-4228-BCB7-04E94AE5CAB5Q36968260-6B8E5E5B-38A2-4075-9F69-55D915CA85C7Q37574221-34746D96-3394-4A96-8D68-9AE2B8172E3AQ37740679-145D8349-DA98-4379-938E-6F6A20D761A8Q37848296-D86F0785-2D13-4438-B7C4-44290D65D8D8Q37867100-16F1AD66-AEA8-4605-8C41-B5984EF0B679Q37896455-EAF29D59-F56D-47B3-8BA8-ED0526F2AE10Q38061423-DB7DC990-1E21-43C6-A6AD-3936125DD5CBQ38124062-D85C7578-2435-4ACA-9A9E-B1938E712307Q38210198-40E1E39E-FCF2-48FE-89C5-329BF94F28C9Q38292668-F70D31C2-262E-4471-B0F2-FE03BCE3904AQ38979453-4333E7E7-05CB-4B35-8A21-1E364AA1EFCDQ40141953-64852E9B-3859-490B-919D-67F6B1E0E4AFQ40159983-E84769ED-A7C7-4DE8-B73F-FE3AC9C19D37Q45872770-77D660C8-2284-4092-A31C-4AFAB2613C3DQ54647504-96E57E61-A745-42F4-8111-243094447508Q58493224-F83EC238-D8F4-4D0A-A9B9-C4E964302190
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Virosomes for antigen and DNA delivery.
@ast
Virosomes for antigen and DNA delivery.
@en
type
label
Virosomes for antigen and DNA delivery.
@ast
Virosomes for antigen and DNA delivery.
@en
prefLabel
Virosomes for antigen and DNA delivery.
@ast
Virosomes for antigen and DNA delivery.
@en
P2093
P50
P1476
Virosomes for antigen and DNA delivery.
@en
P2093
Arjan de Mare
Jørgen de Jonge
Laura Bungener
P304
P356
10.1016/J.ADDR.2004.09.005
P407
P577
2005-01-01T00:00:00Z